Josh Lehrer, Graphite Bio CEO

Graphite Bio leads this week's IPO squad, look­ing to turn the tide on sick­le cell dis­ease with gene edit­ing

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

Biotech’s IPO march con­tin­ued ear­li­er this week with Monte Rosa pric­ing on Thurs­day, and now Fri­day’s bunch heads to Nas­daq led by gene edit­ing play­er Graphite Bio.

Lo­cat­ed in South San Fran­cis­co, Graphite is go­ing pub­lic Fri­day on the heels of a $238 mil­lion raise less than 10 months af­ter get­ting start­ed with a Se­ries A. It’s been a rapid as­cent, CEO Josh Lehrer told End­points News, but he feels the com­pa­ny is now at the point where it can fo­cus both on drug de­vel­op­ment and fur­ther build­ing out its plat­form.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.